Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455853 | 1.00 | GPR119 (0.44) | GPR119MAP4K4OPRM1OPRD1OGFRL1 | |
| SCHEMBL30480339 | 0.90 | MAP4K4 (0.52) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL25248226 | 0.90 | MAP4K4 (0.52) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL25407146 | 0.83 | GPR119 (0.45) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL30338079 | 0.83 | GPR119 (0.45) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL25408541 | 0.77 | GPR119 (0.40) | GPR119MAP4K4OPRM1OPRD1OGFRL1 | |
| SCHEMBL24319891 | 0.77 | GPR119 (0.59) | GPR119HRH3 | |
| SCHEMBL27027530 | 0.75 | MAP4K4 (0.55) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL21460217 | 0.75 | GPR119 (0.54) | GPR119OPRM1OPRD1OGFRL1HRH3 | |
| SCHEMBL20046465 | 0.74 | HRH3 (0.51) | GPR119OPRM1OPRD1OGFRL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4192588-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | disclosed |
| CN-115835911-A | Imidazo [1,2-a ] pyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, CNKSR1, UACA | GPR119 231/4885MAP4K4 1298/4885OPRM1 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.